Electroconvulsive Therapy in Clozapine-resistant Schizophrenia

Niuvanniemi Hospital20 enrolled

Overview

Electroconvulsive therapy (ECT) is one of the oldest neuromodulation treatments still used in psychiatry. Only case reports and open label non-randomized studies have been published of ECT in clozapine-resistant schizophrenia patients. The purpose of this trial is to study the efficacy and cognitive effects of add-on ECT treatment (10-course) in schizophrenia patients taking clozapine.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Schizophrenia Schizoaffective Disorder

Interventions

electroconvulsive therapyDEVICE

10-course, three times a week bilateral frontotemporal ECT

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of schizophrenia or schizoaffective disorder * treatment-resistant to clozapine * age 18 - 64 years * capacity and willingness to give informed consent Exclusion Criteria: * serious somatic illness * progressive neurological illness, recent brain damage or sequela of serious brain damage * ECT less than 3 months prior to this trial

Locations (1)

Niuvanniemi Hospital

Kuopio, Finland

RECRUITING

Outcomes

Primary Outcomes

Positive and Negative Symptom Scale

Positive and Negative Symptom Scale (PANSS) is assessed two days after ECT course

Time frame: 2 days

Central Contacts

Eila Tiihonen, MD, PhD

CONTACT

+358 295 242 204 eila.tiihonen@niuva.fi

Soile Hyvärinen, MD

CONTACT

+358 295 242 219 soile.hyvarinen@niuva.fi

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.